Application of a hemophilia mortality framework to the Emicizumab Global Safety Database
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.15187
Abstract: As the first nonâfactor replacement therapy for persons with congenital hemophilia A (PwcHA), emicizumab's safety profile is of particular interest to the community. read more here.
Keywords: mortality framework; application hemophilia; hemophilia mortality; safety ... See more keywords